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Abstract: Alzheimer’s disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million 
people worldwide. A number of different risk factors have been implicated in AD, however, neuritic (amyloid) plaques 
are considered as one of the defining risk factors and pathological hallmarks of the disease. Complement proteins are inte-
gral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest 
stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimer's dementia. This re-
view emphasizes on the dual key roles of complement system and complement regulators (CRegs) in disease pathology 
and progression. The particular focus of this review is on currently evolving strategies for design of complement inhibitors 
that might aid therapy by restoring the fine balance between activated components of complement system, thus improving 
the cognitive performance of patients. This review discusses these issues with a view to inspiring the development of new 
agents that could be useful for the treatment of AD. 
Key Words: Alzheimer’s disease, neurodegeneration, inflammation, -amyloid peptide, complement, complement regulators, 
CD59, complement therapeutics. 
INTRODUCTION 
  Alzheimer disease (AD) is a neurodegenerative disease 
that causes changes in brain function. AD usually affects 
people over the age of 65 years, with a progressive decline in 
memory, thinking, language and learning capacity. Age is 
the strongest predictor for the development and progression 
of AD and with the rapidly aging population, AD clearly 
poses a major health problem. An estimated 5-10% of the 
population aged 65 years and over, and 40% of the popula-
tion older than 85 years of age are likely to be affected by 
AD [48]. Genetic predisposition accounts for only 5-10% of 
the risk of AD and is most pronounced in those developing 
disease at an early age [5, 11].  
  With the aging population in Western countries and the 
annual economic cost of AD in terms of both healthcare ex-
penses and lost wages, it is important to understand the dis-
ease mechanism and propose effective treatment. AD is di-
agnosed post-mortem by analysis of brains of patients with 
dementia. Senile (also called amyloid) plaques and intracel-
lular neurofibrillary tangles (NFT) are considered to be 
hallmarks of the disease [50]. Senile plaques contain ex-
tracellular deposits of amyloid- protein (A), -synuclein, 
ubiquitin, and apolipoprotein E. NFT are intracellular and 
extracellular aggregates of hyperphosphorylated tau protein 
and apolipoprotein E [40]. A is derived from the -amyloid 
precursor protein (APP) by the proteolytic action of - and -
secretases [59]. These enzymes cleave at the N-terminus of 
A region of APP followed by cleavage at the C terminus 
producing peptides that are 39 to 42 amino acids in length.  
*Address correspondence to this author at Department of Medical Biochem-
istry & Immunology, School of Medicine, Cardiff University, Heath Park, 
Cardiff CF14 4XN, UK; Tel: +44(0)2920687868;  
E-mail: donevrm@cardiff.ac.uk 
The predominant two forms found in amyloid plaques and 
believed to be associated with disease are 40 and 42 amino 
acids long. Alternatively the -secretase cleaves APP within 
A domain yielding a non-toxic C terminal fragment, fol-
lowed by its -secretase cleavage to a C terminal fragment-
and a small peptide called P3 that is not considered amyloi-
dogenic. Evidence that A alone is not sufficient for devel-
opment of AD came from experiments with transgenic mice, 
which suggested that sustained brain inflammation might be 
an essential factor in AD pathogenesis. Different inflamma-
tory markers such as activated microglia and astrocytes, ele-
vated levels of various cytokines and complement activation 
products are found in the AD brain [41]. mRNA for all com-
plement components are detected in brain cells, suggesting 
local biosynthesis, and levels of C1q and C9 mRNA are 
markedly upregulated in AD brain [66]. Furthermore, com-
plement proteins are reported to be integral components of 
amyloid plaques and cerebral vascular amyloid in AD brains. 
They are found at the earliest stages of amyloid deposition 
and their activation coincides with the clinical expression of 
Alzheimer's dementia [1, 8]. 
  Here we review the key role of the complement system in 
neurodegeneration and prospective strategies for protection 
of neurons from complement-mediated death.  
THE COMPLEMENT SYSTEM 
  The pathogenesis of AD is not yet fully clear. Various 
hypotheses with respect to disease etiology have been pro-
posed (comprehensively reviewed in [40]). It is likely that 
different primary risk factors synergize to initiate pathology. 
Due to the exceptionally complex events involved in neu-
rodegeneration in AD and their mutual relationship and con-
trol, it is difficult to identify the primary cause of the disease. 
However, it is obvious that the complement system plays a 
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ronal death [8]. The complement system is comprised of 
more than 30 plasma and membrane-bound proteins (Fig. 
(1)) and is activated by three pathways: the classical, alterna-
tive and lectin [60]. The classical pathway (CP) is initiated 
when C1q binds to immune complexes containing IgG or 
IgM resulting in generation of the C3 convertase. The alter-
native pathway (AP) does not require antibodies to initiate 
the cascade, but is triggered by foreign surfaces. This path-
way is continuously ticking-over in plasma, due to spontane-
ous low-level hydrolysis of an internal thioester bond in 
plasma C3. This ensures an immediate and rapid response in 
the face of a foreign surface, such as a bacterium. The lectin 
pathway is activated following recognition and binding of 
MBL to repetitive carbohydrate patterns on the surface of 
pathogenic bacteria and viruses. Binding of MBL to patho-
gens activates the MBL-associated serine protease 2 (MASP-
2) that leads to activation of C4 and C2, the pathway pro-
ceeds in exactly the same way as the CP [54].  
  All three pathways result in formation of a C3 conver-
tase. Further C3 is cleaved to C3b which clusters around the 
initiating convertase and eventually forms an enzyme, the C5 
convertase, capable of binding and cleaving the first compo-
nent of the lytic pathway, C5. C5 is cleaved to C5b, exposing 
a binding site for the next component C6. By sequential as-
sociation of the terminal components (C6, C7, C8 and C9) 
the membrane attack complex (MAC) is formed, this com-
plex is a ‘pore’ which crosses target membranes resulting in 
osmotic lysis and cell death [14].  
  Due to continuous low level turnover of complement in 
plasma, host cells are constantly at threat from ‘accidental’ 
complement deposition. To survive this threat, cells express 
complement regulatory proteins which have evolved to pro-
tect self cells from damage by homologous complement. 
Some of these complement regulators (CRegs) are soluble, 
plasma proteins (C1-inhibitor (C1INH), C4b-binding protein 
Fig. (1). The complement system in AD. Binding of C1q and C3 to amyloid plaques can activate the classical and alternative pathways of 
complement system. No binding of MBL to amyloid plaques and activation of the lectin pathway has been reported. Activation of comple-
ment results in cleavage of C3 and C5 by specific enzymes (C3- and C5-convertases) followed by formation of membrane attack complex 
and cell lysis. Complement is regulated by soluble and membrane bound complement regulators shown in gray boxes. Implication of Complement System  Current Neuropharmacology, 2009, Vol. 7, No. 1    3
(C4bp), factor H (fH), factor I (fI)), whereas others are ex-
pressed on cell membranes (CD46 (also called membrane 
cofactor protein, MCP), CD55 (also called decay accelerat-
ing factor, DAF) and CD59) [29]. CD59 is the only mem-
brane molecule that regulates the terminal complement 
pathway by binding to C8 and thus preventing formation of 
lytic MAC [13]. 
COMPLEMENT ACTIVATION IN AD  
  Although viewed for years as an immuno-privileged or-
gan, the central nervous system (CNS) contains and synthe-
sizes many components of the immune system. Both glia and 
nerve cells in the brain can synthesize complement compo-
nents [3, 51]. Primary astrocytes and astroglia were shown to 
produce all of the components of both the AP and CP, and 
also those proteins involved in the terminal pathway (Fig. 
(1)) [18, 19, 33, 45]. Although CSF levels of MBL have 
been found to be reduced by 44% in AD patients compared 
to control subjects [25], there is no evidence for direct in-
volvement of the lectin pathway in activation of complement 
in AD. Nerve cells can express all of the complement com-
ponents and should also be considered as an important 
source of complement [17]. Thus, the local production of 
complement components in the brain ensures the complete 
functionality of the complement system without the need of 
infusion of plasma-derived complement proteins.  
  Neuritic plaques and NFT comprise the major neuropa-
thological lesions [49]. Neuritic plaques contain degenerat-
ing axons and dendrites and extracellular deposits of A that 
include abundant amyloid intermixed with non-fibrilar forms 
of this peptide. A has several forms with different peptide 
lengths. As discussed above, the two major forms A40 and 
A42 and the short form A28 are predominant in the dis-
ease progression. Fibrillar A40 and A42 directly activate 
the AP and CP in vitro by binding to C3 and the globular 
heads of C1q [24]. It should also be noted that A interac-
tions with C1q lead to increased amyloid aggregation [61], 
which additionally stimulates activation of the complement 
system in AD brains. These interactions trigger the covalent 
binding of C3b to A and subsequent cleavage of C5 into 
two fragments - C5a which promotes inflammation and C5b 
which mediates formation of the lytic membrane attack 
complex (MAC). The MAC then permeabilizes the mem-
brane of the neurons [8], resulting in cellular lysis. Thus, 
activation of the complement system not only leads to cell 
death, but also results in formation of proinflammatory 
molecules C3a, C5a and MAC. The role of these proinflam-
matory molecules in the progression of AD will be discussed 
below. In addition to the above, non-fibrillar A42 and the 
short A28 forms of the amyloid peptide can induce dose-
dependent activation of C4. The mechanism of C4 activation 
is not dependent on C1q, because non-fibrillar A can still 
activate C4 in plasma genetically deficient in C1q. This may 
occurs via activation of contact/kinin system which has been 
shown to be markedly activated in CSF of AD patients [4]. 
Other complement activators, such as amyloid P, C-Reactive 
Protein (CRP) and Hageman factor, were found in AD le-
sions and their potential role for the progression of the dis-
ease has been reviewed elsewhere [31]. All these data dem-
onstrate the existence of multiple ways for activation of 
complement cascade in AD, all of which however are trig-
gered either by the amyloid plaques or by non-fibrillar A.
Thus, generation of amyloid peptides, both soluble and in-
soluble, is a major mechanism for activation of complement 
system in AD brains.  
  Interestingly, a post-mortem study of AD brains showed 
markedly upregulated levels of mRNA for complement 
components in the affected areas of AD brains [66]. In the 
entorhinal cortex, hippocampus and midtemporal gyrus, with 
high accumulation of plaques and tangles, up to 80-fold in-
crease in expression of C1q mRNA and also higher C3, C4 
and C9 mRNA levels were detected. The levels of mRNA 
produced from these complement component genes in com-
partments of the brain affected by disease were even higher 
than in the livers from the same patients, suggesting local 
overproduction of the complement components in AD. The 
detailed molecular mechanisms leading to this local overex-
pression of complement components in AD brains are yet to 
be elucidated, however at present it is widely accepted that 
cytokine expression in the brain stimulates secretion of com-
plement components locally. On the other hand, other studies 
using RT-PCR, RNA in situ hybridizations and immunohis-
tochemical methods show that levels of complement inhibi-
tors in AD are barely increased [2]. Taken together, these 
facts indicate a major role of complement system activation 
in the pathology and progression of AD and the C1q mole-
cule takes a central place in activation of complement cas-
cade. 
Can Complement Activation be also Good for Neurons?  
  There is recent evidence that complement may also play 
a protective role in AD brain. The most convincing data for a 
protective role of complement shows that production of C5a 
results in activation of the neuroprotective mitogen activated 
protein kinases (MAPK) [35]. In support of this, animals 
genetically deficient in the complement component C5 were 
found to be more susceptible to hippocampal excitotoxic 
lesions [36]. These findings suggest a novel non-inflam-
matory role for C5a in modulating neuronal responses to 
excitotoxins. More recently, a protective role of complement 
in AD was demonstrated in human APP transgenic mice; 
when complement was blocked by expression of soluble 
Crry (a rodent CReg with inhibitory activities similar to hu-
man CD46 and CD55) [63], mice expressing soluble Crry 
had a 2-3-fold increase in A accumulation and neuronal 
degeneration compared to animals that did not express the 
inhibitor. Crry inhibits C3 activation, and thus prevents gen-
eration of C5a. Therefore, the observed effect might also be 
due to decreased C5a formation. In another recent study, C1q 
protected cultured primary neurons against A and SAP (se-
rum amyloid P) induced neurotoxicity [39]. The exact 
mechanism of this protection has not been elucidated but the 
data suggest that the effect of C1q was not through inhibition 
of apoptosis in the neurons. However, considering the pro-
tective role of C5a, the C1q-mediated defense against senile 
plaques might be at least in part due to the generation of the 
anaphylatoxin. This speculation is supported by a recent in
vivo study in C3 deficient APP transgenic mice that demon-
strated accelerated plaque deposition and neurodegeneration 
compared to C3 sufficient animals [30].  4    Current Neuropharmacology, 2009, Vol. 7, No. 1 Kolev et al. 
  MAC was also demonstrated to have a dual role in neu-
ronal death. Besides the osmotic lysis it could cause, an in-
teresting hypothesis suggests that at sublytic concentrations, 
MAC can alter the function of neurons by triggering various 
cellular signaling pathways [8]. This process has not been 
investigated in neurons; however, a study using Schwann 
cells as a model system [22] indicated that sublytic MAC 
rescued cell from apoptosis via activation of PI-3 kinase-Akt, 
followed by MAPK/ERK1 signaling cascade and increased 
expression of the anti-apoptotic regulator Bcl-xL. Therefore, 
sublytic MAC detected on Schwann cell in vivo during in-
flammatory neuropathy may facilitate survival of Schwann 
cell.  
  In summary, complement may have a dual role in patho-
genesis and progression of AD and this should be carefully 
considered when choosing targets for development of thera-
peutics.  
ALTERATIONS IN EXPRESSION OF COMPLEMENT 
REGULATORS IN AD 
  As reviewed above, activation of the complement system 
may be both beneficial and detrimental in AD. Therefore, it 
is of a great importance to understand whether expression of 
the complement regulators (CRegs) alters as a result of the 
disease. Astrocytes and microglia in the CNS produce both 
soluble CReg (clusterin – controls the lytic activity of the 
MAC, C1INH, fH, fI, C4bp, properdin – a major regulator of 
the AP which stabilizes C3bBb convertase) and membrane-
bound CReg (CD59, CD55, CD46) [18, 58], which ensures a 
good level of protection against complement activation. 
However, the same cannot be said for neurons. There is very 
little information regarding expression of the CRegs in neu-
ronal cells. Studies to date suggest that cultured primary neu-
rons only express low levels of the membrane CReg, CD59 
(lower than the astrocytes), and CD55, and secrete only 
C1INH and clusterin [37, 57]. In NT2-N neuronal cell lines, 
relatively high expression levels of CD46, CD59 and CD55 
are found [38], however, NT2-N are differentiated from 
NTERA-2 tumour cells (malignant pluripotent embryonal 
carcinoma) and tumours are known to overexpress these 
CReg proteins [6, 46]. Our unpublished data demonstrate 
that neurons differentiated from human neural progenitor 
cells express very low levels of the three membrane-bound 
CReg. Hence, neurons are particularly susceptible to com-
plement-mediated death.  
  Studies on the effect of AD on expression of CRegs in 
neurons are few in number. Although the importance of this 
issue is clear, it has been overlooked for years. In a compara-
tive study carried out on RNA samples from AD patients and 
matched controls, it was reported that C1INH and CD59 
expression was slightly upregulated in AD brains [65]. How-
ever, this analysis was performed by a semi-quantitative 
PCR and the reported upregulation of 17% and 12%, respec-
tively, are unlikely to be significant. Moreover, limited over-
expression of CRegs in the face of markedly increased ex-
pression of complement components C1r (206%), C1s 
(167%), C5 (135%), C6 (156%), C7 (142%), C8 (408%) and 
C9 (1530%) implies that neurons in AD brains may be very 
susceptible to complement attack [32]. In another study it 
was demonstrated at both protein and mRNA levels that 
CD59 expression in frontal cortex and hippocampus in AD 
brains was significantly decreased when compared with 
normal age matched non-demented individuals [64], support-
ing the hypothesis that AD brains are particularly vulnerable 
to complement-mediated neuronal death. Although the data 
on expression of CRegs in AD are very limited, all studies 
demonstrated that expression levels of inflammatory media-
tors are markedly upregulated in AD tissue while those of 
the complement inhibitors are altered only slightly. This 
lends further support to the hypothesis that chronic inflam-
mation may be causing neuronal death in AD. 
  Another mechanism that is likely to contribute to the sus-
ceptibility of neurons to complement lysis, which could be 
spontaneously activated [47, 68], was demonstrated using 
IMR32 neuroblastoma cells as a model. Loss of all CRegs 
expressed on the surface of these cells (CD46 and CD59) by 
shedding into the culture medium was detected in neurons 
during apoptosis, which for example, could be initiated by 
the amyloid plaques. Activation of caspases in human neu-
rons does not lead to an immediate and rapid process of cell 
death but provokes a protracted form of apoptosis [69]. Thus 
caspase activation in neurons may participate in the long-
term overproduction of A, which is consistent with the pro-
tracted and age-dependent nature of AD Therefore, the shed-
ding of membrane-bound CReg results in an increased sus-
ceptibility to complement-mediated lysis [12]. This might be 
one of the mechanisms resulting in decreased expression of 
the membrane-bound CReg proteins in AD brains. Further-
more, as a result of the lost CRegs, these apoptotic cells are 
likely to activate the complement system, yielding increased 
local inflammation and contributing to AD related neuronal 
damage.  
TREATMENT TARGETING THE COMPLEMENT 
SYSTEM  
  AD is a complex disease and its management is often 
challenging. Personality and behavioural changes, and the 
eventual inability to perform activities of daily living lead to 
dependence. A cure for AD is still not available and clini-
cians and caregivers are challenged with caring for an in-
creasingly aging population affected by dementia. The pri-
mary goals of treatment are to maximize the patient’s ability 
to function in daily life, maintain quality of life, slow the 
progression of symptoms, and treat depression or disruptive 
behaviors. However, at present, all treatments for AD offer 
only modest symptomatic relief for periods of between six to 
eighteen months. Some of the currently used/researched 
agents for treatment of the disease are considered to pre-
vent/delay AD symptoms, which may be of a great benefit 
for significantly reducing the number of patient with demen-
tia. There are a number of different categories of drugs used 
or under research in AD treatment (reviewed in [28]). Here 
we emphasize therapeutic agents that target the complement 
system. Until now complement proteins and CRegs have 
been overlooked as targets for development of drugs for AD 
treatment, but accumulated data suggest that appropriate 
modulation of expression and/or activity of proteins control-
ling the complement cascade would be beneficial for AD 
patients. Here we review the current, rather unsatisfactory 
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speculate on the future developments of complement inhibi-
tor therapeutics.  
Cerebrolysin 
  Cerebrolysin (CBL) is an anti-inflammatory mixture of 
neuropeptides (smaller than 10kDa) obtained from porcine 
brain tissue [44]. It exhibits unique neurotrophic and neuro-
protective activity and reduces amyloid burden in animal 
models. It also improved neurodegenerative alterations in an 
APP model of AD [43]. CBL regulates the activity of cyclin-
dependant kinase-5 and glycogen synthases kinase 3, which 
phosphorylate APP, thus reducing levels of phosphorylated 
APP and accumulation of APP in neuritic processes [44]. 
This reduces the level of available APP for cleavage by the 
secretases. Studies in patients with mild to moderate AD 
have shown that CBL improves cognitive performance [47]. 
However, considering the complex nature of CBL (produced 
by standardised enzymatic breakdown of purified porcine 
brain proteins and containing approximately 25% of low 
molecular weight peptides (<10 k DA) and a mixture of ap-
proximately 75% free amino acids), this therapeutic may 
well have other features that benefit AD patients. For exam-
ple, we recently found that CBL protects cultured human 
neurons differentiated from neural stem cells from comple-
ment-mediated lysis by upregulation of expression of CD59 
and CD55 (Kolev et al., submitted). This multilevel effect of 
CBL on neurons, anti-inflammatory, anti-apoptotic and local 
inhibition of complement on neuronal surface, justify the 
need of additional well-designed studies, adequately pow-
ered, to assess the beneficial properties of CBL. 
Antibody Inhibitors of Complement  
  Perhaps the most successful soluble therapeutic agents 
have been antibody-based agents, either full-length immuno-
globulin or single-chain Fv (scFv) fragments. The most ex-
tensively studied therapeutic antibodies are against C5. Anti-
bodies that bind C5, thereby preventing triggering of the 
terminal pathway and MAC formation, have been successful 
in treatment of various pathologies exacerbated by comple-
ment activation. Anti-C5 in particular is used for treatment 
of paroxysmal nocturnal hemoglobinuria (PNH), and is be-
ing developed further for treating myocardial infarct (MI) 
and arthritis [9, 10, 23]. Such antibodies, however, would 
prevent generation of C5a, which was demonstrated to be of 
a benefit for clearance of amyloid plaques in animal models 
of AD. Antibodies have also been generated which target 
and inhibit other components of the terminal pathway, in-
cluding C6 and C8. Anti-C8 was shown effectively to inhibit 
platelet activation in a bypass model, indicating that specific 
blockade of MAC function might be of therapeutic benefit 
[42]. Considering the data about the role of complement sys-
tem in AD (reviewed above), these agents are very promis-
ing for management of AD, however, the consequence of 
such treatment has yet to be tested in vivo in AD animal 
models. 
Inhibitors of Amyloid-Mediated Complement Activation 
  Amyloid plaques can activate complement via binding 
C1q, resulting in bystander killing of neurons and driving 
neurodegeneration. Therefore, molecules that could inhibit 
this interaction might have therapeutic potential on the neu-
rodegeneration reducing its progress. Glycosaminoglycans 
were demonstrated to have an inhibitory effect on the inter-
action between C1q and A [56]. A similar structure – activ-
ity relationship as on the SAP component – A interaction 
was shown. This suggests that glycosaminoglycans interfere 
with the binding site on A for SAP component and C1q.  
  Another inhibitor of the complement system, C4bp, also 
was detected in amyloid plaques and on apoptotic cells in 
AD brain [67]. A very recent study [55] showed that under in 
vitro conditions, C4bp binds apoptotic and necrotic but not 
viable brain cells (astrocytes, neurons and oligodendrocytes) 
and limited complement activation on dead brain cells. C4bp 
also binds A42 peptide directly via the C4bp -chain limit-
ing the extent of complement activation by A. These recent 
findings suggest that C4bp, respectively C4bp-derived pep-
tides and glycosaminoglycans might be used for therapeutic 
modulation of complement activation against excessive 
complement activation in AD brains. 
Soluble Forms of Membrane CReg 
  In addition to the molecular approach described above, a 
plethora of soluble therapeutics has been developed which 
specificallyinhibitthecomplement cascade [34]. Early agents 
were based on the naturally-occurring membrane-associated 
CRegs, such as CD46, CD55, CD59 and Complement Re-
ceptor 1 (CR1; CD35). Removal of membrane-anchoring 
domains using recombinant technology generated soluble 
molecules with the same regulatory functions as the ‘parent’ 
inhibitor, which could be administered locally or systemi-
cally to inhibit complement. The best known of these is a 
soluble form of CR1 (sCR1), an agent developed nearly 30 
years ago and used in the clinic, with limited success, for 
complement inhibition in MI and cardiopulmonary bypass 
(CPB) [26, 27, 62]. These ‘first-generation’ agents have been 
engineered and modified over the years to improve charac-
teristics such as half-life (by introducing antibody Fc do-
mains; [21]), membrane localisation (by using lipid ‘tails’; 
[52]) and by targeting specifically to sites of complement 
activation (by using fusion proteins comprising a domain 
that binds C3 activation fragments, thus localising to the site 
of complement attack [53]). In the case of AD, it may be 
beneficial to selectively inhibit the complement cascade. For 
example, inhibition of the terminal pathway using antibodies 
that allow C5a formation but prevent MAC formation may 
prevent neuronal damage but permit the observed protective 
effects of C5a. Another agent, developed to selectively in-
hibit MAC formation, but which allow C5a generation, is a 
CD59-Ig fusion protein [7]. This has been tested in a murine 
model of laser-induced choroidal neovascularization and 
shown to have therapeutic effect. This long-lived agent halts 
the complement cascade at the level of C8. The problem with 
many of these agents is that their action is systemic, totally 
blocking the complement cascade. In addition, if they are 
targeted to the alternative, classical or MBL activation path-
ways, their long-term use can be detrimental, triggering im-
mune complex disease and permitting bacterial infections as 
the key role of complement in innate immunity is prevented. 
Recently we have designed a strategy that renders the active 
component inactive as a prodrug, which activates at sites of 
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vation of prodrugs at sites of chronic inflammation including 
the CNS in AD.  
Antibody-CReg Hybrid Molecules as Potential Comple-
ment Therapeutics in AD 
  Agents that specifically target complement inhibition to 
the vicinity of the amyloid plaques would avoid systemic 
inhibition of complement, and provide enhanced protection 
to neurons. Previous in vitro studies have demonstrated that 
recombinant techniques can be used to fuse CReg to the car-
boxy-termini of antibodies or antibody Fab fragments, thus 
locating the therapeutic action of the inhibitor to the site pre-
determined by antibody specificity [68]. If recombinant anti-
bodies to A, or other antigens unique to the plaque, are de-
veloped, then specific targeting of CD59 or other agents to 
sites of disease may be possible. This approach has not been 
yet studied in animal models of AD, however, we believe it 
has a great potential in preventing complement-mediated 
neuronal degeneration and needs further attention.  
Targeting CReg Genes in AD 
  Recently, we have proposed a new strategy for modula-
tion of expression of membrane-bound CRegs by targeting 
transcriptional regulators of their genes [15, 16]. We showed 
that p53 and neuronal-restrictive silencer factor (REST) are 
potential targets for modulation of expression of CD59 in 
neurons. We further elucidated the REST-dependent mecha-
nism for suppression of CD59 expression and designed sev-
eral peptides that could modulate expression of this CReg. 
One of these peptides up-regulated CD59 in IMR32 neuro-
blastoma cells and human neurons differentiated from neural 
progenitor cells by 5-fold at both mRNA and protein levels 
(Kolev  et al., submitted). Further analysis of the potential 
benefits from this overexpression is undergoing, however, it 
is clear that the CD59 up-regulation results in local suppres-
sion of the MAC on neuronal surface, whilst allowing forma-
tion of beneficial complement activation products, such as 
C5a [36]. This approach seems very promising for diseases 
like AD, although further investigation is needed to clarify 
potent activators of CReg expression and optimize methods 
for delivery. DNA-binding sites of transcription factors are 
highly conserved between species, therefore this approach is 
translatable to the murine system where adequately powered 
in vivo studies should be carried out. 
CONCLUSIONS 
  AD is the most common cause of dementia in people 
over age of 65 and affects more than 24 million people 
worldwide. This number will increase considerably in the 
future and will present enormous financial burdens to health 
care systems. The need for effective treatment is urgent. Cur-
rent drugs for treating the cognitive impairments in AD are 
based on neurotransmitter replacement or modulation, which 
produce mild symptomatic benefit with minimal impact on 
the disease process. The role of inflammation in AD pathol-
ogy is increasingly recognized and anti-inflammatory agents 
suggested as therapy. The complement system and its regula-
tors have been shown to play a key role in neuronal death 
and represent an attractive target in AD. Preventing comple-
ment activation triggered by amyloid plaques by blocking 
the interaction between complement proteins and A, or by 
inhibiting the proteolytic cascade of complement activation 
may reduce neuronal loss. The apparent neuroprotective ef-
fect of some complement activation products emphasises the 
“double-edged sword” nature of complement in this disease. 
As a consequence, the choice of agent and stage of activation 
targeted will be crucial for success of anti-complement 
therapies in AD. Further experiments are needed in vitro and 
in animal models in order to choose drugs which inhibit gen-
eration of ‘disease-associated’ complement activities while 
retaining the ‘beneficial’ ones, thus providing a maximal 
benefit to AD patients.  
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